SCHEMBL387263

SCHEMBL387263

CC(C)(C)Oc1ccc(C=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.58
CYP2A6 P11509 3/20 0.58
ALDH1A3 P47895 1/20 0.52
STS P08842 1/20 0.45
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
KDM4E B2RXH2 2/20 0.42
DRD1 P21728 1/20 0.42
TYR P14679 1/20 0.41
CYP2A13 Q16696 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP3 Q9Y6F1 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH5A1 P51649 1/20 0.41
ABAT P80404 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10803692 0.87 ALDH1A1 (0.50) ALDH1A1CYP2A6ALDH1A3STSLMNA
SCHEMBL934183 0.83 ALDH1A1 (0.54) ALDH1A1CYP2A6ALDH1A3STSLMNA
SCHEMBL7333886 0.82 CYP2A6 (0.44) ALDH1A1CYP2A6ALDH1A3HPGDDRD1
SCHEMBL7711579 0.81 SLC6A2 (0.37) ALDH1A1CYP2A6ALDH1A3LMNAMAPT
SCHEMBL26746 0.80 SLC6A2 (0.44) ALDH1A1MAPTHPGDKDM4EKMT2A
SCHEMBL7184445 0.79 ALDH1A1 (0.48) ALDH1A1CYP2A6LMNAMAPTKDM4E
SCHEMBL9998062 0.79 ALDH1A1 (0.48) ALDH1A1CYP2A6LMNAMAPTKDM4E
SCHEMBL10389057 0.79 ALDH1A1 (0.50) ALDH1A1CYP2A6ALDH1A3STSLMNA
SCHEMBL6414094 0.79 ALDH1A1 (0.37) ALDH1A1CYP2A6ALDH1A3LMNAMAPT
SCHEMBL20090430 0.78 ALDH1A1 (0.48) ALDH1A1CYP2A6ALDH1A3STSLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504388-A Preparation method and application of tert-butyl aryl ether 贵港市微芯科技有限公司 2025-02-25 CN claimed
US-20070112000-A1 Chemical compounds ASTRAZENECA R&D ALDERLEY (GB) 2007-05-17 US claimed
EP-1684757-A1 SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME AstraZeneca AB (SE) 2006-08-02 EP claimed
WO-2005046685-A1 SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME ASTRAZENECA AB (SE) 2005-05-26 WO claimed
US-5965591-A MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE SANKYO COMPANY, LIMITED (JP) 1999-10-12 US claimed
EP-0064702-B1 4-TERT.-BUTOXYBENZYL AMINES BASF Aktiengesellschaft (DE) 1984-05-02 EP claimed
EP-0025883-B1 ELECTROCHEMICAL PROCESS FOR THE PREPARATION OF 4-TERT.-BUTOXY-BENZALDEHYDE-DIALKYLACETALS, THEIR USE AND 4-TERT.-BUTOXY-BENZALDEHYDE-DIMETHYLACETAL BASF Aktiengesellschaft (DE) 1983-01-12 EP claimed
EP-0064702-A1 4-Tert.-butoxybenzyl amines BASF Aktiengesellschaft (DE) 1982-11-17 EP claimed
EP-0059372-A1 Process for the preparation of 4-tert.-butoxybenzyl alcohol BASF Aktiengesellschaft (DE) 1982-09-08 EP claimed
JP-3044349-A None JP disclosed
EP-4104902-B1 COMPOUNDS AND MEDICAMENTS USING SAME IRIMAJIRI THERAPEUTICS INC (JP) 2026-05-27 EP disclosed
US-20260028554-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES OSMO LABS PBC (US) 2026-01-29 US disclosed
CN-119822934-A Preparation method of p-tert-butoxystyrene 上海八亿时空先进材料有限公司 2025-04-15 CN disclosed
CN-119504388-A Preparation method and application of tert-butyl aryl ether 贵港市微芯科技有限公司 2025-02-25 CN disclosed
EP-0059372-A1 Process for the preparation of 4-tert.-butoxybenzyl alcohol BASF Aktiengesellschaft (DE) 1982-09-08 EP disclosed
EP-0058326-A1 Process for the preparation of araliphatic aldehydes and/or amines BASF Aktiengesellschaft (DE) 1982-08-25 EP disclosed
EP-0038480-A1 Process for the preparation of 1-(4-hydroxyphenyl)-3-butanone and intermediate compounds for this process BASF Aktiengesellschaft (DE) 1981-10-28 EP disclosed
EP-0034253-A2 4-Tert.-butoxy-phenyl-glycine nitrile, and process for the preparation of D-(-)- and L-(+)-4-hydroxy-phenyl glycine BASF Aktiengesellschaft (DE) 1981-08-26 EP disclosed
EP-0025883-A1 Electrochemical process for the preparation of 4-tert.-butoxy-benzaldehyde-dialkylacetals, their use and 4-tert.-butoxy-benzaldehyde-dimethylacetal BASF Aktiengesellschaft (DE) 1981-04-01 EP disclosed
EP-0025883-A1 Electrochemical process for the preparation of 4-tert.-butoxy-benzaldehyde-dialkylacetals, their use and 4-tert.-butoxy-benzaldehyde-dimethylacetal BASF Aktiengesellschaft (DE) 1981-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112000-A1 Chemical compounds HSD11B1, CYP11B1, HSD11B2 ALDH1A1 68/4885CYP2A6 108/4885ALDH1A3 335/4885
US-20260028554-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES TAS2R42, TAS2R4, TAS2R41 ALDH1A1 868/4885CYP2A6 535/4885ALDH1A3 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.